As CD93+-selected populations have functional properties of CML LSC, with evidence of increased engraftment potential, we hypothesized that those cells with less CD93 expression would have a more mature and less lineage-restricted gene expression profile compared with LSC-CD93+ cells. The gene discussed is CD93; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.